Correlation of VEGF with contrast enhancement on dual-phase dynamic helical CT in liver tumors: Preliminary study

Journal of Korean Medical Science

Volumn 16, Issue 1, 2001, Pages 83-87

  Kwak, Byung Kook ^a,d   Shim, Hyung Jin ^a   Park, Un Sub ^a   Lee, Tae Jin ^a   Paeng, Sung Suk ^b   Lee, Chang Jun ^b   Lim, Hyo K ^c   Park, Cheol Keun ^c  

^a Chung Ang University   (South Korea)

^b National Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

Author keywords

Computed Tomography, Contrast Enhancement; Computed Tomography, Helical; Liver; Liver Neoplasms; Liver Neoplasms, Blood Supply; Vascular Endothelial Growth Factor (VEGF)

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CAPILLARY PERMEABILITY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMAGE QUALITY; LIVER TUMOR; MALE; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; VASCULARIZATION;

ADULT; AGED; CAPILLARY PERMEABILITY; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE ENHANCEMENT; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035260932     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2001.16.1.83     Document Type: Article

References (25)

1. Knopp MV, Hoffmann U, Brix G, Hawighorst H, Junkermann HJ, van Kaick G. Fast MRI contrast medium dynamics for characterization of tumors. Experiences with functional MR- mammography. Radiologe 1995; 35: 964-72.
2. Furman-Haran E, Margalit R, Grobgeld D, Degani H. Dynamic contrast enhanced magnetic resonance imaging reveals stress- induced angiogenesis in MCF7 human breast tumors. Proc Natl Acad Sci USA 1996; 93: 6247-51.
3. Krause W, Schuhmann-Gampieri G. Pharmacokinetics of contrast media. In: Dawson P, Claub W, eds. Contrast media in practice. Berlin, Pa: Springer Verlag, 1994; 26-34.
4. Almen T. Relations between chemical structure, animal toxicity and clinical adverse effects of contrast media. In: Enge I, Edgren J, eds. Patient safety and adverse events in contrast medium examinations. Amsterdam, Pa: Elsevier Science, 1989; 25-56.
5. Knopp MV, Weiss E, Sinn HP, Mattem J, Junkermann HJ, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10: 260-6.
6. Strugar J, Rothbart D, Harrington W, Criscuolo GR. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994; 81: 560-6.
7. Gryspeerdt S, Hoe LV, Marchai G, Baert AL. Evaluation of hepatic perfusion disorders with Double-phase Spiral CT. Radiographics 1997; 17: 337-48.
8. Bonaldi VM, Bret PM, Reinhold C, Atri M. Hepatic CT of the liver: value of an early hepatic arterial phase. Radiology 1995; 197: 357-63.
9. Lautt WW, Greenway CV. Conceptual review of the hepatic vascular bed. Hepatology 1987; 7: 952-63.
10. Baron RL. Understanding and optimizing use of contrast material for CT of the liver. Am J Roentgenol 1994; 163: 323-31.
11. Wolf KJ, Steidle B, Skutta T, Mutzel W. Iopromide: clinical experience with a new nonionic contrast medium. Acta Radiol Diagn (Stockh) 1983; 24: 55-62.
12. Groothuis DR, Vriesendorp FJ, Kupfer B, Wamke PC, Lapin GD, Kuruvilla A, Vick NA, Mikhael MA, Patlak CS. Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann Neurol 1991; 30: 581-8.
13. Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC. Vascular endothelial growth factor expression, vascular volume, and capillary permeability in human brain tumors. Neurosurgery 1999; 44: 732-41.
14. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8.
15. Connolly D, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgthber RM, Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
16. Obermair A, Kohlberger P, Bancher-Todesca D, Tempfer C, Sliutz G, Leodolter S, Reinthaller A, Kainz C, Bbreitenecker G, Gitsch G. Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 1996; 63: 204-9.
17. Senger DR, Connolly D, Perruzzi CA. Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium. Fed Proc 1987; 46: 2102.
18. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-8.
19. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
20. Kumar R, Yoneda J, Fidler IJ. Distinct biologic activities of different angiogenic molecules. In Proceeding of the 88th Annual Meeting of American Association for Cancer Research, San Diego, CA, 1997; 53 (abstr).
21. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93: 14765-70.
22. Jain RK. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1997; 4: 1-23.
23. Roberts WG, Hasan T. Tumor-secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake. Cancer Res 1993; 53: 153-7.
24. Kim KJ, Winder J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-4.
25. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993; 194: 1234-41.